Courier Capital Corp buys $3,025,062 stake in Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb Co (BMY) : Courier Capital Corp scooped up 602 additional shares in Bristol-Myers Squibb Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 40,442 shares of Bristol-Myers Squibb Co which is valued at $3,025,062.Bristol-Myers Squibb Co makes up approximately 0.59% of Courier Capital Corp’s portfolio.

Other Hedge Funds, Including , Wheatland Advisors Inc reduced its stake in BMY by selling 800 shares or 2.52% in the most recent quarter. The Hedge Fund company now holds 30,900 shares of BMY which is valued at $2,311,320. Bristol-Myers Squibb Co makes up approx 1.21% of Wheatland Advisors Inc’s portfolio.Meag Munich Ergo Kapitalanlagegesellschaft Mbh reduced its stake in BMY by selling 66,854 shares or 41.34% in the most recent quarter. The Hedge Fund company now holds 94,882 shares of BMY which is valued at $7,098,122. Bristol-Myers Squibb Co makes up approx 0.62% of Meag Munich Ergo Kapitalanlagegesellschaft Mbh’s portfolio.Round Table Services reduced its stake in BMY by selling 139 shares or 4.31% in the most recent quarter. The Hedge Fund company now holds 3,087 shares of BMY which is valued at $236,063. Bristol-Myers Squibb Co makes up approx 0.13% of Round Table Services’s portfolio.Chesley Taft Associates reduced its stake in BMY by selling 825 shares or 4.39% in the most recent quarter. The Hedge Fund company now holds 17,974 shares of BMY which is valued at $1,360,272. Bristol-Myers Squibb Co makes up approx 0.14% of Chesley Taft Associates’s portfolio.Ls Investment Advisors reduced its stake in BMY by selling 652 shares or 0.8% in the most recent quarter. The Hedge Fund company now holds 80,632 shares of BMY which is valued at $6,102,230. Bristol-Myers Squibb Co makes up approx 0.41% of Ls Investment Advisors’s portfolio.

Bristol-Myers Squibb Co opened for trading at $74.96 and hit $75.62 on the upside on Thursday, eventually ending the session at $75.32, with a gain of 0.70% or 0.52 points. The heightened volatility saw the trading volume jump to 34,74,924 shares. Company has a market cap of $125,849 M.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Initiated by Hilliard Lyons to “Neutral” on May 23, 2016.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.